Overview

• Cytokinetics Q3 net loss widens to $306.2 mln, driven by debt conversion expense

• Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year

• Cytokinetics prepares for potential U.S. launch of aficamten pending FDA approval

Outlook

• Company expects EMA decision on aficamten MAA in 1H 2026

• Company updates 2025 GAAP operating expense guidance to $680 mln-$700 mln

• Cytokinetics prepares for aficamten U.S. commercial launch post-PDUFA date

Result Drivers

• FDA INTERACTIONS - Co progressing towards Dec 2025 PDUFA date for aficamten, with strategic commercial preparations underway

• R&D EXPENSES: $99.2 million for the third quarter of 2025

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cytokinetics Inc is $79.00, about 24.5% above its November 4 closing price of $59.62

Press Release: ID:nGNX8Mgh2m

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)